Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 120,312 Shares of Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 120,312 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $2.50, for a total value of $300,780.00. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $156,465. This represents a 65.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.
• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total value of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total value of $150,000.00.

Equillium Price Performance

Shares of NASDAQ EQ opened at $2.32 on Tuesday. The company has a market cap of $141.26 million, a price-to-earnings ratio of -3.74 and a beta of 1.80. The stock’s 50-day moving average is $1.55 and its two-hundred day moving average is $1.42. Equillium, Inc. has a 1-year low of $0.27 and a 1-year high of $2.70.

Institutional Investors Weigh In On Equillium

Several institutional investors have recently added to or reduced their stakes in EQ. ADAR1 Capital Management LLC boosted its holdings in Equillium by 0.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after purchasing an additional 48,090 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Equillium during the fourth quarter worth approximately $9,057,000. Balyasny Asset Management L.P. raised its holdings in Equillium by 3.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock worth $3,218,000 after purchasing an additional 72,602 shares in the last quarter. Cantor Fitzgerald L. P. lifted its position in shares of Equillium by 32.4% during the 4th quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company’s stock worth $872,000 after buying an additional 137,643 shares during the last quarter. Finally, Diadema Partners LP lifted its position in shares of Equillium by 15.8% during the 4th quarter. Diadema Partners LP now owns 347,393 shares of the company’s stock worth $538,000 after buying an additional 47,393 shares during the last quarter. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EQ. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research note on Monday, December 29th. Zacks Research upgraded shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. Stifel Nicolaus began coverage on shares of Equillium in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target for the company. Roth Mkm initiated coverage on shares of Equillium in a research report on Friday. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.